

BLADDER  
CANCER  
AWARENESS  
MONTH  
— MAY —





# Bladder Cancer Support Group

***Influence of Nutrition on Cancer***

***Special Guest: Diana Mills, MS, RND***

Suzanne B. Merrill, M.D., F.A.C.S. & Lauren Sheffield, P.A.

*Bladder Cancer Team*

*Colorado Urology*

*personal care*  
The most personal care for life's most personal issues.®

**Colorado**  
**UROLOGY**

# 1<sup>st</sup> Walk to End Bladder Cancer— Denver

April 27, 2024



Colorado Urology Team  
Awarded the Largest  
Team





# 2024 Bladder Cancer Facts

## FACTS ABOUT BLADDER CANCER



This year, **more than 83,000 people** in the US will receive a bladder cancer diagnosis



Bladder cancer is the **7th most commonly diagnosed cancer** in the United States



Bladder cancer is the **4th most common cancer** in men



Women often have a **delayed diagnosis and have worse outcomes** than men at every stage of the disease.

## Actively Enrolling Bladder Clinical Trials

### BCG Unresponsive High Risk (HR)

#### SUNRISE 1 (Janssen)

- HG Ta/T1 papillary only
- TAR-200 Alone

#### BOND (CG Oncology)

(planned opening)

- HG Ta/T1 papillary only
- Cretostimogene induction + maintenance

### Recurrent HR NMIBC

#### SUNRISE 5 (Janssen)

- Re-Occurred after BCG
- TAR 200 vs Investigator's choice of intravesical MMC or GEM

### BCG Naïve HR NMIBC

*BCG Naïve defined as not having received prior BCG or stopped more than 3 years prior to study entry*

#### SUNRISE 3 (Janssen)

- TAR-200 in Combination with Cetrelimab versus BCG Alone
- BCG provided by study

#### PATAPSCO (AstraZeneca)

- Single Arm, Open Label BCG with Durvalumab
- BCG provided by study

#### QUILT 2005 (ImmunityBio)

(planned opening)

- BCG with ALT 803 (IL-15 superagonist) vs BCG alone

### BCG Exposed HR NMIBC

#### Keynote (Merck)

- Post BCG Induction - MUST HAVE CIS
- BCG +/- Keytruda vs BCG alone
- BCG provided by study

### Intermediate Risk (TaLG) NMIBC

#### MOONRISE (Janssen)

- FGFR + patients only (genetic testing completed on all potential patients at screening)
- TAR 210 with Erdafitinib (every 12 week instillation) vs MMC or GEM

#### PIVOT (CG Oncology)

- Adjuvant Cretostimogene Grenadenorepvec vs Observation following TURBT

### Muscle Invasive

#### SUNRISE 2 (Janssen)

- cT2-T4a N0, M0
- TAR-200 in combination with Cetrelimab vs. chemotherapy + radiation

#### SUNRISE 4 (Janssen)

- cT2-T4a N0, M0
- Open Label TAR-200 plus Cetrelimab prior to cystectomy vs. Cetrelimab alone prior to cystectomy

# The Influence of Nutrition

# Colorado UROLOGY®

*The most personal care for life's most personal issues.®*

[www.coloradouro.com](http://www.coloradouro.com)

***Thank you!***

BLADDER  
CANCER  
AWARENESS  
MONTH  
— MAY —



# Bladder Cancer Support Group

*Colorado Urology*

- Semi-annual to quarterly meetings
- *Share your email*
  - Continue the community support throughout the year!
- *Meeting topics*
  - What do you want to learn about?
    - Upcoming clinical trials and therapeutics
    - Ostomy tips/tricks
    - Pelvic floor physical therapy
    - Ways to mitigate side effects of intravesical therapy
    - Novel treatments for metastatic bladder cancer



I'AM A  
WARRIOR

BLADDER CANCER AWARENESS



BLADDER CANCER AWARENESS

